Even in ‘normal’ times a reliable supply of medical oxygen is an essential part of healthcare services, but during COVID-19 surges the need for this life-sustaining gas has spiked to unprecedented levels. Tiyese Jeranji explores the fascinating science and engineering that facilitates this substance’s long journey from a production plant to a person’s lungs.
Treating highly drug-resistant forms of tuberculosis can take anything from nine to 24 months and patients have to contend with various unpleasant, and sometimes dangerous, side effects. A new six-month regimen made up of just three drugs that will be offered to 400 patients in South Africa might offer a better solution for some. Tiyese Jeranji reports.
A study published in the Lancet medical journal confirms that the health effects of COVID-19 can linger months after someone has ‘recovered’. Kathryn Cleary asked local experts about the underlying science and whether the South African public healthcare system is ready for so-called long-COVID.
New World Health Organization guidance released this week endorses the wider use of chest X-rays and artificial intelligence for tuberculosis detection. Before these technologies can be fully utilised in South Africa, some regulatory and other issues will first have to be sorted out. Catherine Tomlinson reports.
In August last year, the South African Pollen Monitoring Network expanded pollen monitoring efforts in the country. The data now being collected can assist researchers, doctors, and people with pollen allergies. Elri Voigt explores these efforts and the impact pollen has on the lives of people in South Africa.
Children shoulder approximately 12% of the global TB burden, and this proportion is likely higher in high TB burden countries. In South Africa, up to 30 000 children develop TB each year. Tiyese Jeranji spoke to TB expert, Dr Megan Palmer from Brooklyn Chest Hospital about treatment challenges and how to improve TB detection and treatment outcomes in children.
A new four-month treatment course for drug-sensitive tuberculosis (the most common form of TB by far) is as safe and effective as the current six-month treatment course that has been in use since the 1980s, according to findings from a large new study. Amy Green reports.
